tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RARE Stock Latest News

Ultragenyx Pharmaceutical’s Promising Growth and Financial Outlook: Analyst Recommends Buy
RatingsUltragenyx Pharmaceutical’s Promising Growth and Financial Outlook: Analyst Recommends Buy
23h ago
RARE
Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges
PremiumCompany Announcements
Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges
1d ago
RARE
Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating
PremiumRatings
Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating
2d ago
RARE
Ultragenyx Reports Growth Amidst Strategic Advancements
PremiumCompany Announcements
Ultragenyx Reports Growth Amidst Strategic Advancements
2d ago
RARE
Ultragenyx reports Q2 EPS ($1.17), consensus ($1.32)
PremiumThe Fly
Ultragenyx reports Q2 EPS ($1.17), consensus ($1.32)
2d ago
RARE
Ultragenyx backs FY25 revenue view $640M-$670M, consensus $649.53M
PremiumThe FlyUltragenyx backs FY25 revenue view $640M-$670M, consensus $649.53M
2d ago
RARE
Ultragenyx Pharmaceutical’s Promising Outlook: Buy Rating Affirmed Amidst Aspire Study Progress
Premium
Ratings
Ultragenyx Pharmaceutical’s Promising Outlook: Buy Rating Affirmed Amidst Aspire Study Progress
4d ago
RARE
RARE Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
RARE Earnings this Week: How Will it Perform?
5d ago
RARE
Ultragenyx Completes Enrollment for GTX-102 Phase 3 Study
PremiumCompany Announcements
Ultragenyx Completes Enrollment for GTX-102 Phase 3 Study
7d ago
8K
RARE
Ultragenyx completes enrollment of GTX-102 trial
PremiumThe Fly
Ultragenyx completes enrollment of GTX-102 trial
7d ago
RARE
Ultragenyx assumed with a Buy at H.C. Wainwright
PremiumThe Fly
Ultragenyx assumed with a Buy at H.C. Wainwright
11d ago
RARE
Ultragenyx’s UX111 CRL Not a Major Setback; Focus Remains on Promising Programs with Outperform Rating Maintained
PremiumRatings
Ultragenyx’s UX111 CRL Not a Major Setback; Focus Remains on Promising Programs with Outperform Rating Maintained
24d ago
RARE
Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Manageable FDA Setbacks and Promising Clinical Data
PremiumRatingsUltragenyx Pharmaceutical: Buy Rating Affirmed Amid Manageable FDA Setbacks and Promising Clinical Data
25d ago
RARE
Ultragenyx participates in a conference call with JPMorgan
Premium
The Fly
Ultragenyx participates in a conference call with JPMorgan
25d ago
RARE
Ultragenyx price target lowered to $79 from $80 at BofA
Premium
The Fly
Ultragenyx price target lowered to $79 from $80 at BofA
25d ago
RARE
Positive Outlook on Ultragenyx Pharmaceutical Despite Setback with UX111 Approval
PremiumRatings
Positive Outlook on Ultragenyx Pharmaceutical Despite Setback with UX111 Approval
25d ago
RARE
Ultragenyx announces Health Canada extended approval of Evkeeza
PremiumThe Fly
Ultragenyx announces Health Canada extended approval of Evkeeza
25d ago
RARE
Ultragenyx price target lowered to $55 from $65 at Morgan Stanley
PremiumThe Fly
Ultragenyx price target lowered to $55 from $65 at Morgan Stanley
25d ago
RARE
Ultragenyx falls 4% to $28.41 after FDA rejection letter for gene therapy
PremiumThe Fly
Ultragenyx falls 4% to $28.41 after FDA rejection letter for gene therapy
27d ago
RARE
Ultragenyx Receives FDA Response on UX111 Application
PremiumCompany AnnouncementsUltragenyx Receives FDA Response on UX111 Application
27d ago
8K
RARE
Ultragenyx trading resumes
Premium
The Fly
Ultragenyx trading resumes
27d ago
RARE
Ultragenyx receives CRL from FDA for UX111 gene therapy
Premium
The Fly
Ultragenyx receives CRL from FDA for UX111 gene therapy
27d ago
RARE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >